Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients [PDF]
Diabetes & Metabolism Journal, 2011 BackgroundThe present study investigated the efficacy and safety of vildagliptin-metformin treatment compared to those of glimepiride-metformin treatment for type 2 diabetes.MethodsIn a randomized, open-label, comparative study, 106 patients with type 2 ...
Hyun Jeong Jeon, Tae Keun Oh
doaj +1 more source
The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses [PDF]
, 2014 Inhibitors of dipeptidylpeptidase IV (DPP-IV) represent a novel class of frequently used anti-diabetic drugs. In addition to its function in metabolic regulation, DPP-IV also plays a role in the immune system.
Buhling +11 more
core +1 more source
Indian Journal of Endocrinology and Metabolism, 2012 Objective: Addition of vildagliptin to ongoing insulin therapy may help in terms of overall glycemic control as well as reduction in dose of insulin and weight.
Paresh Ved, Samrat Shah
doaj +1 more source
pharma-kritik, 2008 Mit Vildagliptin steht - neben Sitagliptin - ein weiterer sogen. DPP-4-Hemmer zur Verfügung. Das Medikament senkt das HbA1c weniger stark als Metformin. Daten zu klinisch relevanten Endpunkten liegen noch keine vor.
openaire +1 more source
The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis [PDF]
, 2013 BACKGROUND: Although incretin therapy is clinically available in patients with type 2 diabetes undergoing hemodialysis, no study has yet examined whether incretin therapy is capable of maintaining glycemic control in this group of patients when switched ...
Ayako Takada +17 more
core +1 more source
A Prospective Observational Study to Compare the Efficacy and Adverse Effects of Glimepiride and Vildagliptin Added to Metformin in Type 2 Diabetes Mellitus [PDF]
Journal of Clinical and Diagnostic Research, 2019 Introduction: In order to prevent the specific diabetes mellitus related macrovascular and microvascular complications, guidelines by American Diabetes Association recommend a reasonable glycosylated haemoglobin goal for non-pregnant adults to be less ...
Biswanath Sharma Sarkar +3 more
doaj +1 more source
International Journal of Endocrinology, 2015 The study explored the utility of four-point preprandial glucose self-monitoring to calculate several indices of glycemic control and variability in a study adding the DPP-4 inhibitor vildagliptin to ongoing insulin therapy.
Andrea Tura +5 more
doaj +1 more source
Biomedicines, 2023 The repurposing of drugs is one of the most competent strategies for discovering new antimicrobial agents. Vildagliptin is a dipeptidyl peptidase-4 inhibitor (DPI-4) that is used effectively in combination with metformin to control blood glucose levels ...
Maan T. Khayat +7 more
doaj +1 more source
Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. [PDF]
, 2014 peer reviewedPatients with type 2 diabetes mellitus have an increased risk of chronic liver disease (CLD) such as non-alcoholic fatty liver disease and steatohepatitis, and about one-third of cirrhotic patients have diabetes.
Scheen, André
core +1 more source
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors [PDF]
, 2009 BACKGROUND: Type 2 diabetes is a chronic, progressive disease with a multi-faceted pathophysiology. Beyond the known defects of insulin resistance and beta-cell insufficiency, derangement of incretin hormones normally produced from the gut wall in ...
Berneis, K +4 more
core +1 more source